Background Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a small-and medium-sized vasculitis classically seen in adult patients, with peak onset near the fifth to seventh decade of life. There is little data on ANCAassociated vasculitis in pediatric patients, and most studies have limited follow-up. Methods This is a retrospective chart review of 22 patients with ANCA-positive glomerulonephritis in a single institution from 1991 to 2013. Results Of the 22 patients, eight (36 %) required renal replacement therapy (RRT) at diagnosis; four of these patients recovered sufficient renal function to initially discontinue dialysis. Five patients (23 %) were treated with plasmapheresis at presentation. The median time from presentation until first clinical or serologic relapse was 1.7 ± 1.2 years. After a median follow-up of 5.8 years, just over half of our patients had chronic kidney disease (CKD) stages 1-3 (55 %). Seven (32 %) patients progressed to end-stage renal disease (ESRD) and eventually required kidney transplant.
Introduction
Dr. J. Charles Jennette and Dr. Ronald J. Falk first characterized the association of antineutrophil cytoplasmic antibodies (ANCA) with necrotizing vasculitis in the 1980s and 1990s [1] . ANCA-associated vasculitis (AAV) is a small-or medium-sized vasculitis that has since been classified in to three separate entities: granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA) [2] . It is a disease classically seen in adults and is rare in the pediatric population. The peak age at onset is commonly between the fifth and seventh decade of life [3] . As a result, much data and many treatment protocols are extrapolated from adult data and applied to pediatric patients. Data on ANCA-associated renal disease in children is mostly in the form of case series and retrospective studies with limited follow-up. Similar to other childhood chronic diseases, children with AAV differ from adults in that they have a longer anticipated life span over which their disease must be managed. Peak age of AAV onset in the pediatric population is during late childhood and adolescence, a critical time for growth as well as emotional, physical, and reproductive development [4] [5] [6] . Critical therapeutic decisions must be made to maximize quality of life (QoL) and long-term renal and overall survival rates. Thus, longitudinal data in this patient population is needed to see the potential evolution of disease through childhood, adolescence and into adulthood.
The purpose of this study was to describe pediatric ANCAassociated glomerulonephritis (AGN) at a single center and to compare our experience with previously published adult and pediatric literature.
Methods
This study was approved by the Institutional Review Board (IRB) governing Indiana University School of Medicine. It is a retrospective chart review of 22 patients with ANCApositive glomerulonephritis diagnosed or managed from 1991 to 2013 within the Pediatric Nephrology and Hypertension Division at Riley Hospital for Children at Indiana University Health, a tertiary care center with a pediatric nephrology division in addition to other pediatric subspecialties. The IRB granted a waiver of consent for this study as this was approved as an IRB-exempt study. We identified patients from the university billing system based on the International Classification of Diseases, 9th edn. (ICD-9) codes available to our institution for billing. The following codes generated a list of 213 patients: 446.0, polyarteritis nodosa and allied conditions; 580.4, acute glomerulonephritis: 582.0, chronic glomerulonephritis; 584.5, acute kidney failure with tubular necrosis; 584.9, acute kidney failure. From this list, 23 patients were identified as being ANCA positive. One patient was ANCA positive but upon further review had questionable renal involvement and was excluded; thus, 22 patients with ANCA-positive disease and active renal involvement were included in the study.
Patients were selected if they met the following criteria: (1) ANCA-positive serology with clinical renal involvement and/ or (2) biopsy findings consistent with the diagnosis of ANCApositive glomerulonephritis. Charts were reviewed for demographic information and clinical and laboratory characteristics at presentation, relapse, and most recent follow-up. Patients were considered to have a serologic relapse if their ANCA titer started to rise after a previous period of stability or became positive after having been negative. Patients were considered to have had a clinical relapse if they developed symptoms that required changes in medical therapy. The estimated glomerular filtration rate (GFR) for each patient was calculated using the modified Schwartz equation [7] . Length of follow-up was determined from the time of presentation to the time of transplant or to the time of most recent follow-up for those patients who did not progress to end-stage renal disease (ESRD) or to the date of most recent available clinical information. All patients who progressed to ESRD were transplanted.
Statistics
Statistical analysis was performed using IBM SPSS 23® statistical software. Continuous variables were compared using the Mann-Whitney U test.
Results

Demographic information
One thousand and seventeen patients were diagnosed with glomerulonephritis from 1991 to 2013 at our institution; 22 were identified as having ANCA-positive glomerulonephritis, making the proportion of patients with AGN 2.16 %. Of the 22 with ANCA-positive glomerulonephritis, 13 (59 %) were female. Median age at presentation was 13.7 years [interquartile range (IQR) 11.6-15.7] . Males presented at an older age than females, but this was not statistically significant (p = 0.08). Table 1 presents a summary of patient demographics and presenting characteristics.
Clinical presentation and initial treatment
Twenty of 22 patients had documented systemic symptoms reported at presentation. Diagnosis and initial management took place at outside institutions for two patients. Figure 1 characterizes the percentage of patients with the most common presenting symptoms. The most commonly reported symptoms were respiratory in nature, with 55 % having documented pulmonary or sinus involvement. Other patients presented with nonspecific complaints of body aches, malaise, and fatigue. One patient presented with heart failure requiring ionotropic support.
The renal involvement at presentation varied considerably, details of which are shown in Table 1 . All patients presented with hematuria, proteinuria, or both. Renal biopsy was performed on 21 patients, 19 of which were performed at our institution. One patient had no biopsy due to the critical nature of the patient's condition at presentation. We classified the renal biopsies into the most appropriate histopathologic categories: focal, crescentic, mixed, and sclerotic according to the AGN classification [8] [9] [10] . Of the 20 patients initially diagnosed and managed at our hospital, all were treated with varying regimens at presentation. Every patient received a methylprednisolone pulse (500-2000 mg per dose), varying between two and six doses over 2-12 days. Following administration of pulse-dose steroids, each patient was transitioned to prednisone at 2 mg/kg/day orally up to a maximum of 60 mg/ day. With the exception of four patients, all were treated with cyclophosphamide either orally or IV. Maintenance immunosuppression for each patient was left to the discretion of the treating physician, and therefore, no standard protocol was used. However, maintenance therapy often consisted of a combination of prednisone with another agent, including mycophenolate mofetil, azathioprine, or hydroxychloroquine. One patient was treated with twice-weekly etanercept injections.
Eight patients (36 %) required renal replacement therapy (RRT) at the time of initial presentation: four recovered sufficient renal function to discontinue dialysis, and five (23 %) were treated with plasmapheresis at presentation. The decision to perform plasmapheresis was at the discretion of the attending nephrologist and generally was reserved for those with the most severe disease at presentation or those who had a slow response to initial therapy. One patient who required plasmapheresis did not require concurrent RRT; 3 years following diagnosis, this patient remains off RRT with chronic kidney disease (CKD) stage 3. Of the remaining four patients who required RRT and were treated with plasmapheresis, two recovered renal function, both of whom were able to remain off dialysis at the most recent follow-up, with CKD stage 2 at 3 and 6 years following diagnosis. One of the four patients was able to discontinue continuous venovenous hemofiltration after 25 days, and dialysis duration was unavailable for one patient.
Failure of induction therapy and relapse
Following induction therapy, two patients (9 %) failed to successfully enter remission: One was treated with methylprednisolone pulses and weekly methotrexate, cyclophosphamide IV, and hydroxychloroquine but ultimately died in the acute phase of the illness. In the days leading to up to death, cyclophosphamide and methotrexate were discontinued due to persistent neutropenia. The patient eventually succumbed to complications of pulmonary fibrosis. The other patient was treated with methylprednisolone, cyclophosphamide IV, azathioprine, and mycophenolate mofetil and required dialysis and eventually kidney transplantation.
Twelve patients (55 %) experienced at least one serologic or clinical relapse. Of these patients, nine suffered from solely Figure 2 shows the Kaplan-Meier curve illustrating the relapse-free survival (RFS) for all 22 patients. At least eight patients (67 %) had their first relapse while on immunosuppressive medication. Of them, three relapsed while on mycophenolate mofetil in combination with prednisone, one on azathioprine in combination with prednisone (40 mg) every other day, one on cyclophosphamide in combination with daily prednisone (5 mg), and three relapsed while on prednisone (50 mg, 30 mg, 5 mg, respectively) every other day. Seven patients (32 %) experienced more than one relapse. All three patients with a confirmed clinical component to the first relapse were treated with increases in immunosuppression, including increases in prednisone and mycophenolate mofetil, and in one patient, with the initiation of high-dose methylprednisolone and cyclophosphamide. Despite aggressive treatment, two of these patients progressed to ESRD. Not all serologic relapses were treated with increases in immunosuppressive therapy. Four patients with first-time serologic relapses were documented to have had increases in immunosuppression prescribed by their provider. There was no standardized treatment protocol for treatment of clinical or serologic relapse, so it is difficult to draw conclusions regarding treatment efficacy based on our data.
ESRD and transplant
The median length of time to follow-up for all patients was 5.8 years (IQR 3.0-8.3); two patients were lost to follow-up. Seven (32 %) patients progressed to ESRD and required kidney transplant. Median estimated GFR at the most recent follow-up of patients who did not progress to ESRD was 61.1 ml/min/1.73 m 2 (IQR 49.3-78.0). Median time from presentation to kidney transplant was 3.5 years (IQR 2.0-8.3). Table 2 illustrates renal outcomes. Of the eight patients who required dialysis at presentation, five (63 %) progressed to require kidney transplantation. Median creatinine at presentation for patients who eventually progressed to ESRD was 8.85 mg/dl (IQR 2.4-28.9), and patients who did not progress to ESRD overall trended lower at presentation, with a median of 2.2 mg/dl (IQR 0.9--5.6); however, this difference was not statistically significant.
Two patients who progressed to ESRD did not present with a need for dialysis. Their serum creatinines at presentation was 1.5 mg/dl and 2.7 mg/dl at ages 17.4 and 11.1 years, respectively; one was proteinase 3 (PR3) positive at presentation, while the other patient was actually ANCA negative at presentation and later seroconverted to myeloperoxidase (MPO)-positive disease. One of these patients actually failed induction therapy and the other had frequently relapsing disease with subsequent decline in renal function. No patient in our study had the rare, but reported, complication of disease recurrence in the transplanted kidney.
Discussion
This is one of the largest studies to describe ANCA-positive glomerular disease in children, with one of the longest followup durations to date. To our knowledge, there are only a handful of recent retrospective studies that describe clinical characteristics of children with this disease; data are sparse in terms of long-term follow-up and progression to ESRD. Table 3 provides a summary of previously published data on pediatric AAV with or without renal involvement. In addition, we determined that ANCA-positive glomerulonephritis accounted for 2.16 % of cases of glomerulonephritis at our center, documenting that ANCA-positive glomerulonephritis is rare in pediatric patients. Sacri et al. 2015 [20] No. patients 5 (71) 6 (60) 27 (87) 13 (76) 6 (86) 18 (90) 20 (80) 41 (63.1)
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4 (40) 9 (29) 1 (6) 2 (29) 10 ( Our patient demographics are consistent with those previously reported in the pediatric literature, with peak age of onset during adolescence and a femalepredominant patient population [5, [11] [12] [13] [14] . In the adult literature, it is reported that renal involvement in AAV can be so severe as to require dialysis dependence in 23-60 % of such patients [15, 16] . Our study found that 36 % of patients required dialysis at diagnosis, which is within the range previously reported in the pediatric literature [5, 6, [10] [11] [12] [13] [17] [18] [19] [20] [21] . However, it is important to note that our study is based solely on patients with renal involvement and not those without. This can be misleading when comparing our study to others, as 100 % of our patients had renal involvement and therefore represent the population at highest risk for dialysis.
Even with effective therapies, AAV is a chronic illness. In adults, AAV has been reported to have a 90 % 2-year mortality if left untreated [3] . Modern treatment protocols with high-dose steroids, cyclophosphamide, rituximab, and plasmapheresis have improved the prognosis of this disease, but all are associated with significant morbidities. Also, in adult populations, it is documented that induction therapy fails to induce remission in ∼10 % of patients [3] . Moreover, after induction therapy and remission, many patients experience clinical or serologic relapse, and kidney function has been reported to be inversely associated with relapse rate [22] .
Our study's pediatric data is strikingly similar to adult data with respect to induction therapy and relapsing disease: 10 % of our patients failed to respond to initial therapy, and more than half (55 %) experienced clinical or serologic relapse. Our data also suggest that patients who fail to enter remission with induction therapy and those who have more frequent relapses have a worse renal outcome. However, our study is biased by the assumption that the time of renal involvement was simultaneous with the time of disease onset. This is not always the case for all patients with AAV, as pediatric patients are especially vulnerable to a delay in diagnosis, given the rarity of the disease and variability in presenting signs and symptoms [14, 23] . In addition, the relapse rate in our study was rather high (55 %). This may be a function of follow-up time, with ANCA titers known to fluctuate in individual patients without evidence of clinical disease. Current guidelines do not consider solely a change in ANCA titer a relapse but a time for close clinical and laboratory monitoring.
With regards to overall prognosis, the adult literature reports that older age, female gender, higher serum creatinine, and chronic histologic lesions are predictors for worse renal outcome and overall survival [16] . Of adult patients with AAV, 14-18 % require permanent dialysis, and the disease has a 23-40 % mortality rate by 1 and 5 years, respectively, from diagnosis [16, 24] . In our cohort, data also suggest that a higher creatinine at presentation is a negative prognostic factor in terms of renal prognosis, although results were not statistically significant likely due to the sample size. However, overall renal prognosis and survival is arguably better than that of the adult population despite the fact that seven of our patients (32 %) progressed to ESRD and required a kidney transplant. Just over half of our patients had CKD stages 1-3 (55 %), with the median estimated GFR of 61.1 ml/min/ 1.73 m 2 for patients who did not progress to ESRD at a median of 5.8 years following diagnosis. The mortality rate was much lower (1 patient, 5 %) than reported in adult literature. Additionally, nearly two thirds of our sample had relatively indolent courses and no need for RRT.
This study is a retrospective chart review. As for all studies with this design, there are significant biases and l i m i t a t i o n s . T h e s e l i m i t a t i o n s s h o u l d n o t b e underestimated. For example, documented rises in ANCA titers may have been associated with further clinical symptoms that were not clearly documented in the either the paper or electronic medical record, limiting our ability to truly document a clinical versus a serologic relapse. Two patients were diagnosed at outside institutions and information surrounding their presentation was limited. Additionally, a statistic illustrating the duration from presentation to ESRD in patients who developed ESRD would have been helpful. However, data collection was limited by what was available in patients' charts, and the timing of dialysis initiation was not available for most patients. Sample size is also a relative limitation. However, this disease is uncommon, and although we are a fairly highvolume center, approximately one patient with this disease presents per year at our institution. Nonetheless, our study has a relatively large cohort with a relatively long follow-up when compared with other pediatric literature on the topic. As such, pediatric patients, in contrast to adults, have potentially multiple decades to live with this disease, and understanding it over long periods of time is essential for improving the care of these patients.
Conclusion
ANCA-positive glomerulonephritis is a rare disorder in children. At presentation, the degree of renal involvement is quite variable, ranging from mild to very severe renal injury. However, nearly two thirds of our cohort were without need for RRT at a median follow-up of 5.8 years, indicating that with modern therapies, this disease can be indolent despite the risk of relapse. Nonetheless, more prospective research is required to understand this disease progression in children.
